JP Morgan Private Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $7.88M | Sell |
9,577
-7,743
| -45% | -$6.09M | 0.02% | 415 |
|
|
2023
Q2 | $12.4M | Sell |
17,320
-4,314
| -20% | -$3.33M | 0.06% | 207 |
|
|
2023
Q1 | $17.8M | Sell |
21,634
-7,001
| -24% | -$5.28M | 0.04% | 326 |
|
|
2022
Q4 | $20.7M | Buy |
28,635
+547
| +2% | +$404K | 0.05% | 300 |
|
|
2022
Q3 | $19.3M | Buy |
28,088
+16,365
| +140% | +$10.3M | 0.05% | 291 |
|
|
2022
Q2 | $6.93M | Sell |
11,723
-243
| -2% | -$158K | 0.02% | 496 |
|
|
2022
Q1 | $8.36M | Buy |
11,966
+391
| +3% | +$247K | 0.02% | 488 |
|
|
2021
Q4 | $7.31M | Buy |
11,575
+1,521
| +15% | +$935K | 0.02% | 513 |
|
|
2021
Q3 | $6.08M | Buy |
10,054
+343
| +4% | +$213K | 0.01% | 547 |
|
|
2021
Q2 | $5.42M | Buy |
9,711
+2,964
| +44% | +$1.5M | 0.01% | 570 |
|
|
2021
Q1 | $3.19M | Sell |
6,747
-23,810
| -78% | -$11.6M | 0.01% | 620 |
|
|
2020
Q4 | $14.8M | Buy |
30,557
+2,527
| +9% | +$1.36M | 0.05% | 308 |
|
|
2020
Q3 | $15.7M | Sell |
28,030
-1,699
| -6% | -$1.03M | 0.06% | 251 |
|
|
2020
Q2 | $18.5M | Buy |
29,729
+7,091
| +31% | +$4.02M | 0.08% | 197 |
|
|
2020
Q1 | $11.1M | Buy |
22,638
+9,510
| +72% | +$3.92M | 0.06% | 248 |
|
|
2019
Q4 | $4.93M | Buy |
13,128
+996
| +8% | +$335K | 0.02% | 423 |
|
|
2019
Q3 | $3.37M | Buy |
12,132
+3,391
| +39% | +$1M | 0.02% | 491 |
|
|
2019
Q2 | $2.74M | Buy |
8,741
+26
| +0.3% | +$8.66K | 0.02% | 523 |
|
|
2019
Q1 | $3.58M | Sell |
8,715
-395
| -4% | -$163K | 0.02% | 479 |
|
|
2018
Q4 | $3.4M | Buy |
9,110
+462
| +5% | +$169K | 0.02% | 444 |
|
|
2018
Q3 | $3.49M | Sell |
8,648
-915
| -10% | -$348K | 0.02% | 503 |
|
|
2018
Q2 | $3.3M | Buy |
9,563
+836
| +10% | +$261K | 0.02% | 494 |
|
|
2018
Q1 | $3.01M | Buy |
8,727
+1,389
| +19% | +$483K | 0.02% | 413 |
|
|
2017
Q4 | $2.76M | Buy |
7,338
+109
| +2% | +$44.1K | 0.02% | 427 |
|
|
2017
Q3 | $3.23M | Sell |
7,229
-1,116
| -13% | -$531K | 0.02% | 386 |
|
|
2017
Q2 | $4.1M | Sell |
8,345
-2,970
| -26% | -$1.3M | 0.03% | 339 |
|
|
2017
Q1 | $4.38M | Buy |
11,315
+3,493
| +45% | +$1.29M | 0.03% | 324 |
|
|
2016
Q4 | $2.87M | Buy |
7,822
+2,453
| +46% | +$933K | 0.03% | 371 |
|
|
2016
Q3 | $2.16M | Buy |
5,369
+649
| +14% | +$260K | 0.02% | 418 |
|
|
2016
Q2 | $1.65M | Sell |
4,720
-27
| -0.6% | -$10.4K | 0.02% | 487 |
|
|
2016
Q1 | $1.71M | Sell |
4,747
-932
| -16% | -$384K | 0.02% | 434 |
|
|
2015
Q4 | $3.08M | Buy |
5,679
+265
| +5% | +$144K | 0.03% | 295 |
|
|
2015
Q3 | $2.52M | Sell |
5,414
-2,249
| -29% | -$1.21M | 0.03% | 303 |
|
|
2015
Q2 | $3.91M | Sell |
7,663
-367
| -5% | -$179K | 0.04% | 276 |
|
|
2015
Q1 | $3.63M | Sell |
8,030
-984
| -11% | -$417K | 0.04% | 287 |
|
|
2014
Q4 | $3.7M | Sell |
9,014
-123
| -1% | -$48.4K | 0.04% | 284 |
|
|
2014
Q3 | $3.29M | Buy |
9,137
+894
| +11% | +$300K | 0.04% | 296 |
|
|
2014
Q2 | $2.33M | Buy |
8,243
+1,002
| +14% | +$297K | 0.04% | 271 |
|
|
2014
Q1 | $2.17M | Buy |
7,241
+4,330
| +149% | +$1.33M | 0.04% | 273 |
|
|
2013
Q4 | $801K | Buy |
2,911
+136
| +5% | +$39.1K | 0.02% | 385 |
|
|
2013
Q3 | $868K | Buy |
+2,775
| New | +$730K | 0.02% | 352 |
|
Other funds holding REGN
JP Morgan Private Wealth Advisors's REGN Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 45% in Q3 2023, selling an estimated $6.09M and leaving 9,577 shares worth $7.88M. The position accounts for 0.02% of the portfolio, ranked #415.
JP Morgan Private Wealth Advisors first reported a position in REGN in Q3 2013 and has held it in 41 quarters since. The position peaked at $20.7M in Q4 2022. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.
- JP Morgan Private Wealth Advisors held 9,577 shares of Regeneron Pharmaceuticals worth $7.88M as of Q3 2023.
- JP Morgan Private Wealth Advisors sold 7,743 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $6.09M.
- Regeneron Pharmaceuticals made up 0.02% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #415 holding.
- JP Morgan Private Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 41 quarters since.
- JP Morgan Private Wealth Advisors's Regeneron Pharmaceuticals position peaked at $20.7M in Q4 2022.
- 1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.